Tvardi Therapeutics (TVRD) Interest Coverage Ratio (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Interest Coverage Ratio of 9.43 for Q1 2026, up 93.79% sequentially from 151.74 in Q4 2025, and down 1090.76% YoY from 0.95 in Q1 2025.
Tvardi Therapeutics (TVRD) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Interest Coverage Ratio for 14 years, with the latest figure at 9.43 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 1090.76% year-over-year to 9.43 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39.36 (down 1363.56% YoY) and the FY2025 annual result came in at 24.63, down 12917.44% from the prior year.
- Interest Coverage Ratio improved to 9.43 in Q1 2026 per TVRD's latest filing, from 151.74 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.17 in Q3 2025 and troughed at 220.45 in Q4 2024.
- A 5-year average of 42.19 and a median of 18.46 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2025: Interest Coverage Ratio slumped 4240.46% in 2023, then soared 99.12% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 63.37 in 2022, then decreased by 2.29% to 64.83 in 2023, then sank by 240.07% to 220.45 in 2024, then surged by 31.17% to 151.74 in 2025, then soared by 93.79% to 9.43 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 9.43, 151.74, and 0.17 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.42 |
| 10 | Tvardi Therapeutics | 18.00 Mn | 18.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.43 |
| Dec 31, 2025 | -151.74 |
| Sep 30, 2025 | -0.17 |
| Jun 30, 2025 | -0.52 |
| Mar 31, 2025 | -0.79 |
| Dec 31, 2024 | -220.45 |
| Sep 30, 2024 | -1.30 |
| Jun 30, 2024 | -59.35 |
| Mar 31, 2024 | -21.77 |
| Dec 31, 2023 | -64.83 |
| Sep 30, 2023 | -20.67 |
| Jun 30, 2023 | -65.20 |
| Mar 31, 2023 | -18.46 |
| Dec 31, 2022 | -63.37 |
| Sep 30, 2022 | -9.59 |
| Jun 30, 2022 | -1.50 |
| Mar 31, 2022 | -8.06 |
| Dec 31, 2021 | -69.12 |
| Sep 30, 2021 | -2.33 |
| Jun 30, 2021 | -6.28 |